The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Anti‐VEGF Aptamer (Pegaptanib) Therapy for Ocular Vascular Diseases
Abstract
Abstract: Vascular endothelial growth factor (VEGF) is a central regulator of both physiological and pathological angiogenesis. Pegaptanib, a 28‐nucleotide RNA aptamer specific for the VEGF 165 isoform, binds to it in the extracellular space, leaving other isoforms unaffected, and inhibits such key VEGF actions as promotion of endothelial cell proliferation and survival, and vascular permeability. Pegaptanib already has been examined as a treatment for two diseases associated with ocular neovascularization, age‐related macular degeneration (AMD) and diabetic macular edema (DME). Preclinical studies have shown that VEGF 165 alone mediates pathological ocular neovascularization and that its inactivation by pegaptanib inhibits the choroidal neovascularization observed in patients with neovascular AMD. In contrast, physiological vascularization, which is supported by the VEGF 121 isoform, is unaffected by this inactivation of VEGF 165. In addition, animal model studies have shown that intravitreous injection of pegaptanib can inhibit the breakdown of the blood–retinal barrier characteristic of diabetes and even can reverse this damage to some degree. These preclinical findings formed the basis for randomized controlled trials examining the efficacy of pegaptanib as a therapy for AMD and DME. The VEGF Inhibition Study in Ocular Neovascularization (VISION) trial comprising two replicate, pivotal phase 3 studies, demonstrated that intravitreous injection of pegaptanib resulted in significant clinical benefit, compared with sham injection, for all prespecified clinical end points, irrespective of patient demographics or angiographic subtype, and led to pegaptanib's approval as a treatment for AMD. A phase 2 trial has provided support for the efficacy of intravitreous pegaptanib in the treatment of DME.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Causes and Prevalence of Visual Impairment Among Adults in the UnitedStates
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.477 · Cited by 2,616
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Self-citationLyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1194 · Cited by 1,860
Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies
Ambati, J., Ambati, B. K., Yoo, S. H., Ianchulev, S., & Adamis, A. P. (2003) · Survey of Ophthalmology · doi:10.1016/s0039-6257(03)00030-4 · Cited by 959
Self-citationAn animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice
Ambati, J., Anand, A., Fernandez, S., Sakurai, E., Lynn, B. C., Kuziel, W. A., Rollins, B. J., & Ambati, B. K. (2003) · Nature Medicine · doi:10.1038/nm950 · Cited by 631
Immunological and Aetiological Aspects of Macular Degeneration
Penfold, P. L., Madigan, M. C., Gillies, M. C., & Provis, J. M. (2001) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(00)00025-2 · Cited by 460
FRANK, R. N., AMIN, R. H., ELIOTT, D., PUKLIN, J. E., & ABRAMS, G. W. (1996) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)72066-5 · Cited by 366
Tsutsumi, C., Sonoda, K.-H., Egashira, K., Qiao, H., Hisatomi, T., Nakao, S., Ishibashi, M., Charo, I. F., Sakamoto, T., Murata, T., et al. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0902436 · Cited by 277
Vitrectomy in the management of diabetic retinopathy
Smiddy, W. E., & Flynn, H. W. (1999) · Survey of Ophthalmology · doi:10.1016/s0039-6257(99)00036-3 · Cited by 114
Cited by
Current approaches in SELEX: An update to aptamer selection technology
Darmostuk, M., Rimpelova, S., Gbelcova, H., & Ruml, T. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.02.008 · Cited by 702
Kern, T. S. (2007) · Journal of Diabetes Research · doi:10.1155/2007/95103 · Cited by 614
One-Year Outcomes of the DA VINCI Study of VEGF Trap-Eye in Eyes with Diabetic Macular Edema
Do, D. V., Nguyen, Q. D., Boyer, D., Schmidt-Erfurth, U., Brown, D. M., Vitti, R., Berliner, A. J., Gao, B., Zeitz, O., Ruckert, R., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.02.010 · Cited by 385
The FERM domain: organizing the structure and function of FAK
Frame, M. C., Patel, H., Serrels, B., Lietha, D., & Eck, M. J. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2996 · Cited by 370
A Highlight of Recent Advances in Aptamer Technology and Its Application
Sun, H., & Zu, Y. (2015) · Molecules · doi:10.3390/molecules200711959 · Cited by 316
Metadata
- Authors
- NG, E. W. M., & ADAMIS, A. P.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2006-10
- Volume
- 1082
- Issue
- 1
- Pages
- 151-171
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W2054703112
- Cited by
- 161
- References
- 10
- FWCI
- 7.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti‐VEGF Aptamer (Pegaptanib) Therapy for Ocular Vascular Diseases. https://app.cochat.ai/papers/10.1196/annals.1348.062
- The paper
- NG, E. W. M., & ADAMIS, A. P. (2006). Anti‐VEGF Aptamer (Pegaptanib) Therapy for Ocular Vascular Diseases. Annals of the New York Academy of Sciences. https://doi.org/10.1196/annals.1348.062
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.